Homocysteine as a predictor of cognitive decline in Alzheimer's disease

International Journal of Geriatric Psychiatry

Volumn 25, Issue 1, 2010, Pages 82-90

  Oulhaj, Abderrahim ^a   Refsum, Helga ^a,b   Beaumont, Helen ^a   Williams, Jonathan ^a   King, Elizabeth ^a   Jacoby, Robin ^c   Smith, A David ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OSLO   (Norway)

^c WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; Cognitive decline; Homocysteine; Non linear model

Indexed keywords

ANTIDIABETIC AGENT; APOLIPOPROTEIN E4; CREATININE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

AGED; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; CIGARETTE SMOKING; CLINICAL ASSESSMENT; COGNITION; COGNITIVE DEFECT; CONCENTRATION RESPONSE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLIC ACID BLOOD LEVEL; GROUPS BY AGE; HEART INFARCTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; ONSET AGE; PREDICTION; STATISTICAL MODEL; STROKE; SYSTOLIC BLOOD PRESSURE; VITAMIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; COGNITION DISORDERS; COHORT STUDIES; FEMALE; HOMOCYSTEINE; HUMANS; LONGITUDINAL STUDIES; MALE; NEUROPSYCHOLOGICAL TESTS; NONLINEAR DYNAMICS; PREDICTIVE VALUE OF TESTS;

EID: 75349099978     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2303     Document Type: Article

References (38)

1. Aisen PS, Schneider LS, Sano M, et al. 2008. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. Jama 300: 1774-1783.
2. Burns A, Jacoby R, Levy R. 1991. Progression of cognitive impairment in Alzheimer's disease. J Am Geriatr Soc 39: 39-45.
3. Chui HC, Lyness SA, Sobel E, Schneider LS. 1994. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Arch Neurol 51: 676-681.
4. Clarke R, Birks J, Nexo E, et al. 2007. Low vitamin B-12 status and risk of cognitive decline in older adults. Am J Clin Nutr 86: 1384-1391.
5. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. 1998. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55: 1449-1455.
6. Davidian M, Giltinan DM. 1995. Nonlinear Models for Repeated Measurement Data. Chapman & Hall: London.
7. Ellul J, Archer N, Foy CM, et al. 2007. The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration. J Neurol Neurosurg Psychiatry 78: 233-239.
8. Ernst RL, Hay JW, Fenn C, Tinklenberg J, Yesavage JA. 1997. Cognitive function and the costs of Alzheimer disease: an exploratory study. Arch Neurol 54: 687-693.
9. Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD. 1999. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet 354: 919-920.
10. Homocysteine-Lowering-Trialist-Collaboration. 2005. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a metaanalysis of the randomized trials. Am J Clin Nutr 82: 806-812.
11. Jacobs D, Sano M, Marder K, et al. 1994. Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology 44: 1215-1220.
12. Locascio JJ, Fukumoto H, Yap L, et al. 2008. Plasma amyloid {beta}-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol 65: 776-785.
13. Martins CA, Oulhaj A, de Jager CA, Williams JH. 2005. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology 65: 1888-1893.
14. McCaddon A. 2006. Homocysteine and cognition-a historical perspective. J Alzheimers Dis 9: 361-380.
15. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. 1998. Total serum homocysteine in senile dementia of Alzheimer type. Int. J. Geriatr. Psychiatry 13: 235-239.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
17. Mielke MM, Rosenberg PB, Tschanz J, et al. 2007. Vascular factors predict rate of progression in Alzheimer disease. Neurology 69: 1850-1858.
18. Morris JC, Edland S, Clark C, et al. 1993. The consortium to establish a registry for Alzheimers disease (CERAD). 4. rates of cognitive change in the longitudinal assessment of probable Alzheimers disease. Neurology 43: 2457-2465.
19. Mortimer JA, Ebbitt B, Jun SP, Finch MD. 1992. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology 42: 1689-1696.
20. Nagy Z, Esiri MM, Jobst KA, et al. 1997. The effects of additional pathology on the cognitive deficit in Alzheimer disease. J Neuropathol Exp Neurol 56: 165-170.
21. Pinheiro JC, Bates DM. 2000. Mixed-effects Models in S and S-PLUS. Springer: New York.
22. R-Development-Core-Team. 2004. R: A Language and Environment for Statistical Computing. Austria R Foundation for Statistical Computing: Vienna.
23. Rasmusson DX, Carson KA, Brookmeyer R, Kawas C, Brandt J. 1996. Predicting rate of cognitive decline in probable Alzheimer's disease. Brain Cognition 31: 133-147.
24. Regan C, Katona C, Walker Z, Hooper J, Donovan J, Livingston G. 2006. Relationship of vascular risk to the progression of Alzheimer disease. Neurology 67: 1357-1362.
25. Roth M, Huppert FA, Tym E, Mountjoy CQ. 1988. CAMDEX: The Cambridge Examination for Mental Disorders of the Elderly. Cambridge University Press: Cambridge.
26. Scarmeas N, Brandt J, Albert M, et al. 2005. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol 62: 1601-1608.
27. Seshadri S. 2006. Elevated plasma homocysteine levels: Risk factor or risk marker for the development of dementia and Alzheimer's disease? J Alzheimers Dis 9: 393-398.
28. Shipchandler MT, Moore EG. 1995. Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott IMx analyzer. Clin Chem 41: 991-994.
29. Smith AD. 2008. The worldwide challenge of the dementias: a role for B vitamins and homocysteine? Food Nutr Bull 29: S143-172.
30. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. 1997. Brain infarction and the clinical expression of Alzheimer disease: the nun study. JAMA 277: 813-817.
31. Stern Y, Albert S, Tang MX, Tsai WY. 1999. Rate of memory decline in AD is related to education and occupation: cognitive reserve? Neurology 53: 1942-1947.
32. Stern Y, Liu XH, Albert M, et al. 1996. Application of a growth curve approach to modeling the progression of Alzheimer's disease. J Gerontol A Biol Sci Med Sci 51: M179-M184.
33. Tangney CC, Tang Y, Evans DA, Morris MC. 2009. Biochemical indicators of vitamin B12 and folate insufficiency and cognitive decline. Neurology 72: 361-367.
34. Teri L, McCurry SM, Edland SD, Kukull WA, Larson EB. 1995. Cognitive decline in Alzheimer's disease: a longitudinal investigation of risk factors for accelerated decline. J Gerontol A - Biol Sci Med Sci 50: M49-M55.
35. Vonesh EF, Chinchilli VM. 1997. Linear and Nonlinear Models for the Analysis of Repeated Measurements. Marcel Dekker: New York.
36. Wolfson C, Wolfson DB, Asgharian M, et al. 2001. A re-evaluation of the duration of survival after the onset of dementia. N Engl J Med 344: 1111-1116.
37. Wolstenholme J, Fenn P, Gray A, Keene J, Jacoby R, Hope T. 2002. Estimating the relationship between disease progression and cost of care in dementia. Br J Psychiatry 181: 36-42.
38. Zhu CW, Scarmeas N, Torgan R, et al. 2006. Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease. Neurology 67: 998-1005.